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Purpose: Calcineurin inhibitors are used to prevent graft
versus host disease in allogeneic stem cell transplant re-
cipients. Achieving therapeutic drug levels prior to trans-
plant engraftment decreases the development of graft versus
host disease. The objective of this study is to investigate if
higher initial dosing of calcineurin inhibitors results in a
shorter time to therapeutic drug levels.
Methods: This study, approved by the Institutional Review
Board, is a retrospective chart review comparing two dosing
strategies of cyclosporine and tacrolimus. The following data
was collected: patient age, gender, ethnicity, initial dose of
cyclosporine or tacrolimus, time to therapeutic drug levels,
time to engraftment, change in bilirubin, and change in
serum creatinine. All data was recorded without patient
identiﬁers and maintained conﬁdentially. Data will be
divided into a low initial dosing group and a high initial
dosing group and time to therapeutic drug levels will be
compared. Descriptive statistics will be utilized to compare
starting doses of calcineurin inhibitors and time to thera-
peutic drug levels.
Conclusion: If correlation is shown, allogeneic stem cell
transplant recipients may be able to reach therapeutic drug
levels sooner and further prevent graft versus host disease
which would decrease mortality and morbidity in this high
risk population. Assessment of this dosing protocol may lead
to more aggressive and individualized dosing strategies.454
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High-dose cyclophosphamide (Cy) is a common component
of conditioning regimens that patients receive prior to he-
matopoietic cell transplant (HCT). Due to concerns for
increased risk of toxicity, obese patients at Virginia
Commonwealth University Health System (VCUHS) receive
doses of Cy based on an adjusted body weight (ABW; ABW ¼
[(total body weight [TBW] e ideal body weight [IBW]) x 0.4]
+ IBW) whereas non-obese patients receive doses based on
TBW. However, these practices are inconsistent with the
American Society of Clinical Oncology (ASCO) 2012 guide-
lines, which recommend that obese patients receive full-
dose chemotherapy. Interestingly, these guidelines excluded
patients with hematological malignancies undergoing HCT
from their literature review. Using a retrospective medical
record review, we examined whether there is a difference in
effectiveness and toxicity between obese and non-obese
patients who receive high-dose Cy prior to HCT.
The primary objective of this study was to determine if there
is a difference in toxicity between obese versus non-obese
patients during the ﬁrst 60 days following transplant.
Toxicity was measured as a composite endpoint of overall
toxicity, which was comprised of any grade 3 or 4 non-he-
matological toxicity, the incidence of pulmonary, hepatic,
renal, or cardiac toxicity, and each component individually.Secondary objectives were to compare the differences in
effectiveness between obese and non-obese patients
assessed by relapse at day +100, relapse at one year, death at
one year, chimerisms at days +30, +60, and +90, and the
incidence of acute graft versus host disease (aGVHD).We also
sought to evaluate the difference in time to engraftment and
rates of infection between groups. Chi-squared test and
Fisher’s exact test were used to assess the primary and sec-
ondary endpoints and two-sample t-tests were used to
assess time to engraftment.
Sixty-one patients met the inclusion criteria. Of these, 28
were considered to be obese while 33 were considered to be
non-obese. Mean BMI was 24.7  2.5 in non-obese patients
and 32.5  4.3 in obese patients. The mean Cy dose in non-
obese and obese patients was 56.80  10.4 mg/kg and 48.55
 3.3 mg/kg of TBW, respectively. The rate of overall toxicity
was greater in the obese patients compared to non-obese
patients (82% vs 52%, OR 4.3 [95% CI 1.3-14.1]), which was
driven by a signiﬁcantly greater incidence of renal dysfunc-
tion (79% vs 48%, OR 3.9 [95% CI 1.3-12.1]). There were no
differences in rates of grade 3 or 4 toxicity, hepatic
dysfunction, or any measure of effectiveness between
groups. Although obese patients are at increased risk of
toxicity, they appear to achieve the same effectiveness as
non-obese patients. Since the increased risk of toxicity is due
to increases in grade 2 renal toxicity, there is no evidence to
support changing the dosing practices at VCUHS.455
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High dose IV melphalan is widely used in preparative regi-
mens for hematopoietic cell transplantation. Package insert
recommendations state to prepare doses to a concentration
of </¼ 0.45 mg/mL in Normal Saline (NS) and to infuse
within 60 minutes of reconstitution. When using these rec-
ommendations, many doses must be prepared in volumes of
1000 mL or more which results in infusion rates of up to 2
liters/hour over 30 minutes. Available infusion pumps have
maximum infusion rate of 999 mL/hour, often requiring
doses be prepared in multiple bags and infused simulta-
neously using 2 pumps to ensure a 30 minute infusion time.
Melphalan was found to have 90% or greater stability at 60
and 90 minutes when diluted in NS polyoleﬁn bags to con-
centrations from 0.45 mg/mL to 2 mg/mL e personal
